INTRODUCTION
Each year worldwide more than 750 000 new cases of colorectal cancer are diagnosed, 1 around two-thirds of which arise in the colon. There is compelling evidence for the role of a range of lifestyle factors -including smoking, physical activity and sedentary behaviour, weight and weight change, and diet -in the aetiology of colon cancer in particular. [2] [3] [4] [5] [6] Evidence is also starting to suggest that lifestyle factors may be associated with survival in patients with colon cancer (see, for example, [7] [8] [9] ). Given that many lifestyle factors are potentially modifiable, greater clarity on the role of these in colon cancer outcomes would be of considerable public health importance.
A 2014 report by the US Surgeon General concluded that smoking may be causally related to higher all-cause and cancer-specific mortality and increased risk of second primary cancers. 10 A recent systematic review and meta-analysis of six studies of smoking and colorectal cancer survival estimated that, compared to never smokers, current smokers had significantly increased risk of death [hazard ratio (HR) = 1.26, 95% CI: 1.15-1.37], 11 but the result was based on all-cause mortality which is influenced by the effects of smoking of deaths from diseases other than cancer. 12 Moreover, no distinction was made between cancers of the colon and rectum. Four studies included in the systematic review reported on smoking and survival in colon cancer patients. [13] [14] [15] [16] All described higher risk of death, or shorter survival, among smokers (who were defined in various ways), but results only reached statistical significance in two of the studies. The majority of colon cancer patients undergo surgery and suitable patients with stage II or III disease may receive adjuvant chemotherapy. 17 Studies suggest that short-term post-operative morbidity and 30-day mortality are worse in colorectal cancer patients who smoke. 18, 19 One small study of 284 colorectal cancer patients with pathologically complete resection reported a significant raised hazard ratio in active smokers 20 but no studies appear to have investigated whether smoking is also associated with survival in non-surgical colon cancer patients. Nicotine inhibits apoptosis by chemotherapeutic agents in colon cancer cells 21 but associations between smoking and chemotherapy receipt in colon cancer patients have not been examined. This large population-based cohort study aimed to investigate (i) whether smoking status at diagnosis is an independent prognostic factor for cancer-specific survival in colon cancer and (ii) whether the association varies by whether or not patients undergo cancer-directed surgery or receive chemotherapy.
METHODS

Setting
The study was conducted in Ireland, which has a mixed public-private healthcare system. All residents are entitled to care within the public system. A population-based colorectal cancer screening programme commenced rollout in 2013. Prior to that, screening was not generally available.
Data
The data source was the National Cancer Registry Ireland, which aims to record all cancers newly diagnosed in the population usually resident in Ireland, using an active registration process. Completeness of registration is estimated to be at least 97%. 22 Following standard protocols, trained tumour registration officers collect patient (e.g. date of birth, address at diagnosis), tumour (e.g. cancer site, date of diagnosis) and first course treatment (surgery, chemotherapy or radiotherapy within a year of diagnosis) details for each tumour. The information collected includes patients' smoking status at diagnosis, as recorded in their hospital records. The Central Statistics Office notifies deaths to the Registry, where they are linked to registered cancers, using probabilistic matching methods; this allows dates and causes of death to be identified. For this analysis, all cases of colon cancer diagnosed 1994-2012 (ICD10 C18, n = 24 953) were abstracted from the Registry. Cases were excluded if they had another invasive cancer (other than non-melanoma skin cancer) diagnosed prior to, or following, the colon cancer (n = 3889), had a tumour morphology other than adenocarcinoma (n = 2842) or were identified from death certificates only (n = 56). Ascertainment of deaths was complete to 31 December 2012. Colon cancer-specific deaths were defined as those for which the underlying cause of death was coded as: cancer at the same diagnosis site; cancer of the same body system; cancer of another specified site or cancer of unknown site. 23 In terms of treatment, each case was classified according to whether or not the patient received, within a year of diagnosis: (i) cancer-directed surgery (i.e. colectomy, hemicolectomy limited excision with or without anastomosis, or endoscopic local excision/destruction) and (ii) at least one course of chemotherapy. Age, marital status and sex were available from Registry records. Cases were assigned to one of five deprivation categories based on address of residence at the time of diagnosis. Categories ranged from least (1) to most deprived (5) and were based on a score derived from 2002 census variables 24 ;
the 2002 census was used as this was closest to the middle of the study period. In terms of clinical variables, summary stage at diagnosis was defined according to the UICC classification 25 and grade as well differentiated, moderately differentiated or poorly differentiated/undifferentiated. Cases were categorised as being located in the proximal (ICD10 18.0-18.5) or distal colon (18.6-18.8) or colon not otherwise specified (NOS; 18.9). Smoking status at diagnosis was classified as: never smoked; ex-smoker (had smoked at least once every month in the past but not in the previous year); and current smoker (had smoked at least once every month in the previous year). For 26% of patients, smoking status at diagnosis was unknown. Information was incomplete or missing for tumour stage (4%) and grade (12%), which are important prognostic factors. 26, 27 In total, 36% of patients had missing values for one or more of smoking status, stage and grade. The missing data items in these field were populated by multiple imputation by chained equations based on other available data.
28, 29
Multiple imputation is considered superior to other approaches to dealing with missing data, because it produces less biased estimates than complete case analysis under a range of missing data scenarios and, under other scenarios, is more efficient than complete case analysis. [30] [31] [32] Fifty datasets were generated, in which missing values for smoking status, grade and stage were imputed using multinomial logistic regression including, as covariates, socio-demographic and clinical variables, indicators of cancer-specific death and death from any cause, and time to cancer death (or censor date) and any death (or censor date) (Table S1 ).
Statistical analysis
The primary analysis was based on the dataset containing the imputed data. As recommended, a complete case analysis (considered a sensitivity analysis) was conducted for comparison. 33 Our interest was in associations between smoking and rate of death so cancer-specific survival was the primary outcome and noncancer deaths were censored (as opposed to being considered competing risks). For each patient, survival time was computed from the date of diagnosis to date of death, 5 years of follow-up, or the censoring date (31 December 2012), whichever occurred first. Chi-square tests were used to compare patient-related and clinical characteristics of never, ex-and current smokers at the time of diagnosis. Curves of cumulative incidence of cancer-specific death up to 5-years post-diagnosis were generated by smoking status and -to aid interpretation -similar curves for cumulative incidence of deaths due to other causes. Unadjusted and multivariable hazard ratios for cancerspecific death within 5-years by smoking status were computed using Cox proportional hazards regression. Hazard ratio estimates from the 50 imputed datasets were combined to provide a single estimate with the standard error adjusted for inter-and intra-imputation variance according to Rubin's rules. 34 Variables for inclusion in the multivariable model were selected using a backwards stepwise approach; variables were retained if the Wald test P-value was <0.05. For each covariate, a test for proportionality of hazards was performed 35 and, since the hazards for age and stage were nonproportional, these variables were fitted as strata in the model. Initially, the analysis was done for all cases then repeated for subgroups defined by treatment. Since most treatments are received shortly after diagnosis, four subgroups were created by combining variables for receipt of cancer-directed surgery (yes/no) and receipt of chemotherapy (yes/no). The interaction between smoking and treatment was tested by fitting a cross-product term. Those who die soon after diagnosis have no possibility of undergoing treatment and this complicates comparisons of treated and untreated groups; how this might influence the relationship between smoking and survival is unclear. Therefore, we repeated this analysis using a landmark approach, 36 which involved restricting the analysis to patients who were alive at 6 months post-diagnosis (since almost all treatments had been delivered by 6 months; n = 14 387).
In the sensitivity analysis, we analysed the dataset which included all patients without missing data for smoking status, stage or grade ('complete cases', n = 11 648). We repeated the descriptive analyses and re-ran the final multivariable model to estimate hazard ratios by smoking status. All analyses were done in STATA 11.0 (College Station, Texas, USA).
Review of previous studies
To set our findings in context, we searched Medline for other studies reporting some aspect of survival by smoking status in people with colon cancer. MeSH headings and text word searches were undertaken, combining terms for disease, smoking exposure and outcome. To be eligible studies had to be published as full papers, in the English language, by 30 th November 2016. Information on the study population, sample size, assessment of smoking status, smoking prevalence and hazard ratios for survival by smoking status was abstracted from the papers identified.
RESULTS
Primary analyses: multiple imputed dataset
The analysis included 18 166 incident colon cancers. After imputation, 57% of patients were classified as never smokers at diagnosis, 23% as ex-smokers and 20% as current smokers (Table 1) . Slightly more than half of patients were male, 13% were aged under 55 at diagnosis and 35% were aged 75 or older. Cancer-directed surgery was received by 85% and 38% had chemotherapy. In terms of treatment combinations, 53% had cancer-directed surgery only, 33% had surgery and chemotherapy, 5% had chemotherapy only, and 10% had neither treatment. There were significant associations between smoking status and all of the socio-demographic and clinical variables (chi-square P < 0.01 throughout; Table 1 ). A higher proportion of current smokers was diagnosed under 55, than ex-smokers or never smokers. The proportion of current smokers who lived in the most deprived areas was higher than for ex-and never smokers. Twenty-seven per cent of current smokers had stage IV disease at diagnosis compared to 24% each of exsmokers and never smokers. The percentage of current smokers who had cancer-directed surgery was slightly lower (82%) than among ex-(85%) and never smokers (86%). In contrast, chemotherapy receipt was more common among current smokers (41%) than ex-or never smokers (both 37%).
During the 5-years post-diagnosis, there were 7488 cancer specific deaths. The cumulative incidence of cancer-specific death was highest in the current smokers; the curves for ex-smokers and never smokers were almost identical ( Figure S1a ). For noncancer deaths, the cumulative incidence was consistently higher in current and ex-smokers than in never smokers ( Figure S1b ).
Univariate and multivariable hazard ratios for cancerspecific death by smoking status for all patients are shown in Table 2 . In the univariate analysis, smoking was a significant prognostic factor; compared to never smokers, current smokers had a significantly increased rate of cancer death, while ex-smokers did not. This pattern persisted after adjustment for socio-demographic and clinical variables (sex, marital status, deprivation category, period of diagnosis, grade and tumour location). Compared to never smokers, the hazard ratio for current smokers was raised by 14% and this was statistically significant (multivariable HR = 1.14, 95% CI: 1.07-1.22). The hazard in ex-smokers did not differ from unity (HR = 1.00, 95% CI: 0.94-1.17). Table 3 shows the univariate and multivariable hazard ratios for smoking status in the four treatment groups. There was a significant interaction between smoking and treatment (P = 0.034). A significant association between smoking and cancer-specific death was apparent among patients who had surgery only (P < 0.01); in adjusted analysis, comparing to never smokers, current smokers had a 21% higher rate of cancer death (HR = 1.21, 95% CI: 1.09-1.34) while the rate in ex-smokers was not raised. In the other three treatment groups, current smoking was not associated with a higher cancer death rate.
In the landmark analysis, the same pattern was evident although the test for interaction was no longer statistically significant (P = 0.118). In the surgery only group, current smokers had a significantly higher rate of death (HR = 1.22, 95% CI 1.09-1.34; P < 0.01); the estimates for current vs. never smokers in the other treatment groups did not differ from unity (surgery & chemotherapy: 1.09, 95% CI: 0.97-1.22; chemotherapy only: 1.01, 95% CI: 0.82-1.25; neither surgery nor chemotherapy: 0.99, 95% CI: 0.84-1.17). Table S2 summarises the characteristics of the 11 648 patients in the complete case analysis. The same pattern of association between smoking status and cumulative incidence of cancer-specific death was evident in this analysis as in the primary analysis based on the dataset with imputed values (data not shown). In univariate analyses, current smokers had a 21% higher rate of cancer-specific death than never smokers; this attenuated slightly in the multivariable analysis but remained statistically significant (multivariable HR = 1.17, 95% CI: 1.08-1.26) ( Table S3 ). The hazard ratio for ex-smokers was 0.99 in both univariate and multivariable analysis. There was a significant interaction between treatment and smoking (P < 0.01) and, as in the primary analysis, the association between current smoking and cancer specific death was found only among cases who had surgery without chemotherapy (multivariable HR = 1.28, 95% CI 1.14-1.43) ( Table S4 ). The same pattern, and a significant interaction (P < 0.01), was seen in the landmark analysis (data not shown).
Sensitivity analyses: complete case dataset
Review of previous studies
Eight studies of smoking and survival in colon cancer were identified, six from the USA, one from Canada and one from Germany (Table 4) what time point, they assessed smoking status. The prevalence of current smokers ranged from 7% to 18%. Five studies reported on cancer-specific survival, and four each on disease-free, recurrence-related and overall survival. For cancer-specific, disease-free or recurrencefree survival, all eight studies reported an increased hazard for current vs. never-or non-smokers, but this only reached statistical significance in four studies.
DISCUSSION
In this population-based cohort study -which is, by far, the largest study of smoking at diagnosis and survival in colon cancer -current smokers (but not ex-smokers) had a statistically significant, 14% higher, rate of cancer death compared to never smokers. Although all of the eight previous studies of colon cancer patients reported poorer survival (by at least by one survival measure) in smokers than non-or never smokers, 7, 13-16, 37-39 the association was not statistically significant in four studies and, in one further study, there was a significant reduction in disease-free survival but not in cancer-specific survival. In part, this is likely to be due to the relatively modest sample size and hence limited statistical power of most of the studies. In the studies which reported significant findings, the hazard ratio for current smokers was around 1.5. 7, 15, 16, 39 One reason for the more modest association in the current study than these studies may that our data was from a populationbased cancer registry; the analysis therefore included all (or, at least 97% of) 22 colon adenocarcinomas diagnosed in Ireland during 1994-2012 eliminating any possibility of selection or participation biases. Of the previous studies, none was truly population-based; three of the eight studies sampled potential participants (who could then agree or decline to participate) from a population-based sampling frame 13, 15, 37 and, of these, only one reported a significantly increased hazard for smokers. 15 Another possible explanation for the more modest association in our study is that we adjusted for deprivation. Deprivation is a marker of socio-economic status and past studies have reported positive associations between various markers of socio-economic status and colon cancer survival. [40] [41] [42] Smoking prevalence tends to be higher in people of lower socio-economic status and/or in more deprived areas, 43 and this is also seen in Ireland. 44 Thus, adjustment for deprivation would be likely to attenuate observed associations between smoking and survival. The observed interaction between smoking and treatment, such that the adverse effect of current smoking was limited to patients who had cancer-directed surgery only, is noteworthy. Several studies have convincingly shown more post-operative complications and higher post-operative mortality in colon (or colorectal) cancer patients who smoke. 18, 19 However, these studies mainly considered short-term outcomes (e.g. 30-day mortality). This study therefore adds to the evidence-base by showing that smoking adversely affects 5-year survival in surgically treated patients. Moreover, the landmark analysis, which included patients who had survived 6 months, suggests that the adverse effect of smoking is not limited to the period immediately post-surgery but extends long term. In addition, our results confirm -in a much larger series and at the population-level -the findings of Munro et al. 20 who reported that active smokers (but not ex-smokers) had a significantly increased hazard compared to nonsmokers; and extend these to show that there is no adverse effect of smoking in nonsurgical patients. The consistent results in the landmark analysis indicate our results are not due to immortal time bias. 45 Our findings, and those of Munro et al., 20 suggest that the mechanism(s) by which smoking impacts on colon cancer survival are related, in some way, to surgery. The lack of association between smoking and survival in surgical patients who also had chemotherapy is intriguing. It seems likely that those who receive chemotherapy are fitter, suggesting that the effect of smoking may be stronger (or only evident) in less fit patients. This might usefully be investigated in future studies.
A significant proportion of colon cancers presents as emergencies requiring rapid surgical intervention.
46, 47 A Swedish study found that colon cancer patients with a lower level of education, or lower income, were more likely to present as emergencies 48 and, in analyses of a subgroup of colon cancers in Ireland, 31% of current smokers presented as emergencies compared to 24% of ex-smokers and never smokers combined. Since cases which present as emergencies have higher mortality, 46, 49 this suggests that a higher frequency of emergency presentation among smokers could help explain the observed association. Positive margins are a risk factor for recurrence following resection for colon cancer 17 and a single study has reported a slightly higher rate of radial margin positivity among current smokers (6.4%) than other colon cancer patients (5.1%). 50 However, the overall rate of radial margin positivity appears too low to fully explain the survival differential between current and never smokers. Another possible explanation follows from the observations that smoking induces a systemic inflammatory response 51 and that systemic inflammatory response is a prognostic factor following colorectal resection. 52 Finally, smoking may be a marker for raised levels of the complex glycoprotein carcinoembryonic antigen (CEA), which is a strong prognostic factor in colorectal cancer. 53 Studies among apparently healthy volunteers have found associations between smoking and higher CEA levels. 54, 55 Further investigations of these potential mechanisms would be of considerable value. Like a few previous studies, 38, 56 we found that current smokers were more often diagnosed with more advanced disease. While this might point to a tumour promoting effect of smoking, it may also be due to different patterns of healthcare consultation in smokers and nonsmokers. Further research to better understand this relationship might illuminate the mechanisms by which smoking influences cancer progression.
Strengths and limitations
Although our data were population-based, the fact that they were derived from a cancer registry meant that we did not have information on disease-free survival, nor did we have any information on tobacco exposure other than smoking status at diagnosis. We also lacked information on other lifestyle factors some of which have been related to colon cancer survival and may be associated with smoking. Smoking status was derived from medical records and, as such, may be subject to misclassification. Data suggest that in face-to-face interviews for research studies, few people in the general population misrepresent their use of tobacco products, 57 but whether this holds for cancer patients in discussions with health professionals who are involved in their treatment is less certain. It seems most likely that -due to social desirability bias -any misclassification will be differential, such that current smokers are more likely to have been classified as nonsmokers than vice versa; this would mean that the hazard ratios are biased towards the null and we have underestimated the true association between smoking and survival. We chose to base our analysis on cancer-specific survival rather than overall survival because the latter is likely influenced by the impact of smoking on other major causes of death, notably cardiovascular disease. Cancer-specific survival analyses are reliant on accurate information on cause of death. While it is well recognised that the cause of death recorded on some death certificates is inaccurate, 58 there does not appear to be any published data to suggest that (in)accuracy is differential by smoking status. In addition, the SEER classification of cancer-specific deaths includes cancers at sites outside the body system of interest 23 and, in our study, there were some deaths at sites other Aliment Pharmacol Ther 2017; 45: 788-800than the bowel, but numbers were small (~2% of deaths). Almost half were coded to the lung or liver so probably represent metastases from the primary tumour; others may represent cancers diagnosed before 1994, about which we had no information. Moreover, the rate of noncancer deaths was higher among current smokers and ex-smokers than never smokers in our dataset, providing some reassurance about the accuracy of death certificates and suggesting that the poorer survival observed in smokers is unlikely to be due to noncancer deaths being miscoded as cancer deaths.
Implications
Although not specific to colon cancer, evidence suggests that some cancer patients give up smoking around the time of diagnosis and others want to stop, 59, 60 and that smoking cessation interventions can be successful among patients/survivors. 61, 62 A single trial of a smoking cessation intervention in patients undergoing colorectal resection found no difference in post-operative complication rates between arms, 63 but the sample size was small (n = 60). Further studies are needed to investigate whether smoking cessation around the time of diagnosis improves patients' outcomes, either in the short or longer-term.
CONCLUSIONS
In this large, population-based, cohort study of newly diagnosed colon cancer patients, current smokers (but not ex-smokers) had a significantly increased rate of cancer death compared to never smokers. This effect was limited to those patients who had cancer-directed surgery, suggesting that the mechanism by which smoking impacts on survival is in some way related to surgery. Further research is needed to better elucidate these mechanisms but, meanwhile, continued efforts to encourage smoking prevention and cessation may bring benefits in terms of improved survival from colon cancer.
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